Felipe Osório

Psychiatrist and Clinical Researcher

Data updated

Papers

15 publications

Trials

0 clinical trials

Research Footprint

Felipe Osório appears in 15 tracked papers (2015–2023), most studied alongside Ayahuasca, Psilocybin and LSD, across Depressive Disorders, Anxiety Disorders and Healthy Volunteers.

Most-cited paper: Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial (814 citations).

Frequent co-authors: Rafael dos Santos, Jamie Hallak and Jaime Crippa.

Background & Research

Felipe L. Osório is a clinician-researcher who has contributed substantially to contemporary clinical research on serotonergic psychedelics, with a particular focus on ayahuasca and its effects in mood and anxiety disorders. Using a mixed-methods approach that includes randomised, placebo-controlled proof-of-concept trials, SPECT neuroimaging, and qualitative long-term follow-up, he has helped to characterise both acute antidepressant and anxiolytic effects and the persistence of therapeutic outcomes in people with recurrent depression and social anxiety. Osório is also a frequent co-author on reviews synthesising historical, pharmacological and therapeutic evidence for ayahuasca and related classic hallucinogens, advancing methodological transparency and integration of neurobiological and phenomenological data in the field.